Titleist Asset Management’s Vanguard Health Care ETF VHT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14M Buy
44,378
+59
+0.1% +$18.5K 0.91% 28
2026
Q2
$13.3M Buy
44,319
+605
+1% +$168K 0.89% 26
2026
Q1
$11.9M Buy
43,714
+522
+1% +$149K 0.9% 27
2025
Q4
$12.4M Buy
43,192
+3,548
+9% +$991K 1% 24
2025
Q3
$10.3M Buy
39,644
+2,133
+6% +$535K 0.9% 28
2025
Q2
$9.32M Buy
37,511
+81
+0.2% +$20K 0.92% 26
2025
Q1
$9.9M Buy
37,430
+10,252
+38% +$2.73M 1.15% 19
2024
Q4
$6.89M Buy
27,178
+12,308
+83% +$3.32M 0.79% 26
2024
Q3
$4.2M Buy
14,870
+410
+3% +$114K 0.6% 38
2024
Q2
$3.85M Sell
14,460
-75
-0.5% -$19.7K 0.58% 48
2024
Q1
$3.93M Sell
14,535
-91
-0.6% -$23.9K 0.69% 42
2023
Q4
$3.67M Buy
14,626
+1,191
+9% +$282K 0.68% 37
2023
Q3
$3.16M Buy
13,435
+711
+6% +$173K 0.65% 36
2023
Q2
$3.12M Buy
12,724
+1,819
+17% +$443K 0.61% 34
2023
Q1
$2.6M Buy
+10,905
New +$2.62M 0.55% 48

Other funds holding VHT

Titleist Asset Management's VHT Position: Q3 2026 in Review

Titleist Asset Management increased its Vanguard Health Care ETF (VHT) stake by 0.13% in Q3 2026, buying an estimated $18.5K and bringing the position to 44,378 shares worth $14M. The position accounts for 0.91% of the portfolio, ranked #28.

Titleist Asset Management first reported a position in VHT in Q1 2023 and has held it in 15 quarters since. 363 funds tracked by Wall St. Rank hold VHT as of Q3 2026.

  • Titleist Asset Management held 44,378 shares of Vanguard Health Care ETF worth $14M as of Q3 2026.
  • Titleist Asset Management bought 59 Vanguard Health Care ETF shares in Q3 2026, an estimated $18.5K.
  • Vanguard Health Care ETF made up 0.91% of Titleist Asset Management's portfolio in Q3 2026, its #28 holding.
  • Titleist Asset Management first reported a position in Vanguard Health Care ETF in Q1 2023 and has held it in 15 quarters since.
  • 363 funds tracked by Wall St. Rank held Vanguard Health Care ETF as of Q3 2026.

Based on Titleist Asset Management's 13F filing for Q3 2026, filed 8 Oct 2026.